Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (202)	1/26/1999 2:14:00 PM
From: WWS	Read Replies (2) \| Respond to of 805

Richard, after a talk w/Liz Razee in Investor Relations I no longer expect a PR by CTII explaining their position vis a vis recent research reports of Vescovi and of Snyder. She said that CTII will do PR only for research of their own staff or that they sponsor directly in academia. But she assured me that they're quite aware of these research efforts outside of their own immediate sphere of influence. While the Vescovi research currently lies outside of the scope of their existing agreements with Neurospheres, all other the roads to commercializing the standard applications of the human neural stem cell (as exemplified by the research of Snyder) must pass through the heart of their existing patent neighborhood. I appreciated her prompt (considering the fact that she was across the country in SFran.) and polite response to my inquiry.